23 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
litigation against the issuer of such securities. If any of the holders of ADSs were to bring such a lawsuit against us, we could incur substantial costs … defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an “affirmative defense” in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.
A Trading Plan must either (1
424B5
5n18 0kea
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
2eu9eofa1
9 Feb 21
Prospectus supplement for primary offering
5:24pm
424B5
akty8lte
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
eudpuwsf55zs3ymo
6 Oct 20
Shelf registration (foreign)
4:25pm
6-K
EX-10.1
wbekja
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
F-1/A
oazk4tdadzf8s
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
69sbjqn9n
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
EX-10.1
st16 sn0g
3 Sep 19
Current report (foreign)
4:05pm
20-F
yhen6le1zrsds0
29 Apr 19
Annual report (foreign)
4:59pm
424B3
mfkzpg6
20 Mar 19
Prospectus supplement
4:58pm